Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
deLIVER: DAA Effects on Liver Tissue in HCV and HIV/HCV
NCT02938013Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2017
- Primary completion
- Sep 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of voxilaprevir in hepatitis C (HCV), sponsored by Johns Hopkins University. Started Jan 2017; status: completed.
02
Drugs
voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02938013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938013.